prednisone has been researched along with Fetal Growth Restriction in 19 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The better pregnancy outcome associated with lower prednisone dosage is probably related to the fact that the patients selected to receive the low-dose regimen have had a longer and less complicated post-transplantation course." | 7.69 | Prednisone dosage and pregnancy outcome in renal allograft recipients. ( Bar, J; Boner, G; Fisch, B; Gelerenter, I; Hod, M; Wittenberg, C, 1997) |
| "Treatment with prednisone and aspirin appears to be efficacious, safe, and economic in the prevention of pregnancy loss and fetal growth retardation in patients with aCL." | 7.68 | Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. ( Angel, J; Espinoza, LR; Hubble, CL; Jara, LJ; Martínez-Osuna, P; O'Brien, W; Saway, S; Seleznick, MJ; Silveira, LH, 1992) |
| "(1) Those patients with unstable status progestation, patients being newly diagnosed with SLE during pregnancy or patients irregularly using prednisone became active during pregnancy." | 3.73 | [Influential factors of systemic lupus erythematosus activity during pregnancy and its relationship with pregnancy outcome]. ( Tan, JP; Wang, YH; Wu, XX; Zhang, JP, 2006) |
| "The better pregnancy outcome associated with lower prednisone dosage is probably related to the fact that the patients selected to receive the low-dose regimen have had a longer and less complicated post-transplantation course." | 3.69 | Prednisone dosage and pregnancy outcome in renal allograft recipients. ( Bar, J; Boner, G; Fisch, B; Gelerenter, I; Hod, M; Wittenberg, C, 1997) |
| "Treatment with prednisone and aspirin appears to be efficacious, safe, and economic in the prevention of pregnancy loss and fetal growth retardation in patients with aCL." | 3.68 | Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. ( Angel, J; Espinoza, LR; Hubble, CL; Jara, LJ; Martínez-Osuna, P; O'Brien, W; Saway, S; Seleznick, MJ; Silveira, LH, 1992) |
| " During their next pregnancy, the patients were treated with 40 to 50 mg of prednisone per day and 81 mg of aspirin per day." | 3.67 | Obstetric complications associated with the lupus anticoagulant. ( Branch, DW; Hershgold, E; Kochenour, NK; Scott, JR, 1985) |
| "The risk of preeclampsia and placental insufficiency was substantial and occurred in 50% of patients." | 2.42 | Antiphospholipid syndrome in obstetrics. ( Heilmann, L; Pollow, K; von Tempelhoff, GF, 2003) |
| "Takayasu's arteritis is a chronic and non-specific disease of young women in reproductive age that primarily affects the aorta, its branches and the pulmonary artery." | 1.37 | [Takayasu's arteritis in pregnancy: report seven cases]. ( Carvajal-Valencia, JA; Chacón-Solís, AR; Estrada-Altamirano, A; Hernández-Pacheco, JA; Maya-Quiñones, JL; Valenzuela-Jirón, A, 2011) |
| "In 40 to 50% of DBA patients, congenital abnormalities mostly in the cephalic area and in thumbs and upper limbs have been described." | 1.36 | Diamond-Blackfan anemia, ribosome and erythropoiesis. ( Da Costa, L; Leblanc, T; Mohandas, N; Moniz, H; Simansour, M; Tchernia, G, 2010) |
| "Mean birth weight was 2." | 1.28 | [Pregnancy after renal transplantation. 27 patients and review of the literature]. ( Edouard, D; Fernandez, H; Frydman, R; Ville, Y, 1992) |
| "Polymyositis is a myositic disease that is rarely seen as a complicating condition of pregnancy." | 1.27 | Polymyositis in pregnancy. A case report and literature review. ( Gast, MJ; Houck, W; Melnyk, C, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leroux, M | 1 |
| Desveaux, C | 1 |
| Parcevaux, M | 1 |
| Julliac, B | 1 |
| Gouyon, JB | 1 |
| Dallay, D | 1 |
| Pellegrin, JL | 1 |
| Boukerrou, M | 1 |
| Blanco, P | 1 |
| Lazaro, E | 1 |
| Da Costa, L | 1 |
| Moniz, H | 1 |
| Simansour, M | 1 |
| Tchernia, G | 1 |
| Mohandas, N | 1 |
| Leblanc, T | 1 |
| Hernández-Pacheco, JA | 1 |
| Estrada-Altamirano, A | 1 |
| Valenzuela-Jirón, A | 1 |
| Maya-Quiñones, JL | 1 |
| Carvajal-Valencia, JA | 1 |
| Chacón-Solís, AR | 1 |
| Heilmann, L | 1 |
| von Tempelhoff, GF | 1 |
| Pollow, K | 1 |
| Wang, YH | 1 |
| Wu, XX | 1 |
| Tan, JP | 1 |
| Zhang, JP | 1 |
| Kornacka, MK | 1 |
| Bokiniec, R | 1 |
| Schade, RR | 1 |
| Van Thiel, DH | 1 |
| Gavaler, JS | 1 |
| Wiesner-Bornstein, R | 1 |
| Niesen, M | 1 |
| Grobe-Einsler, R | 1 |
| Schulte-Holtey, M | 1 |
| Huynh, LA | 1 |
| Min, DI | 1 |
| Davies, DP | 1 |
| Carp, HJ | 1 |
| Menashe, Y | 1 |
| Frenkel, Y | 1 |
| Many, A | 1 |
| Nebel, L | 1 |
| Toder, V | 1 |
| Mashiach, S | 1 |
| Framarino di Malatesta, ML | 1 |
| Poli, L | 1 |
| Pierucci, F | 1 |
| Paolucci, A | 1 |
| Pretagostini, R | 1 |
| Di Nicuolo, A | 1 |
| Berloco, P | 1 |
| Alfani, D | 1 |
| Piccioni, MG | 1 |
| Veneziano, M | 1 |
| Bar, J | 1 |
| Fisch, B | 1 |
| Wittenberg, C | 1 |
| Gelerenter, I | 1 |
| Boner, G | 1 |
| Hod, M | 1 |
| Redmond, GP | 1 |
| Silveira, LH | 1 |
| Hubble, CL | 1 |
| Jara, LJ | 1 |
| Saway, S | 1 |
| Martínez-Osuna, P | 1 |
| Seleznick, MJ | 1 |
| Angel, J | 1 |
| O'Brien, W | 1 |
| Espinoza, LR | 1 |
| Ville, Y | 1 |
| Fernandez, H | 1 |
| Edouard, D | 1 |
| Frydman, R | 1 |
| Houck, W | 1 |
| Melnyk, C | 1 |
| Gast, MJ | 1 |
| Lubbe, WF | 1 |
| Liggins, GC | 1 |
| Branch, DW | 1 |
| Scott, JR | 1 |
| Kochenour, NK | 1 |
| Hershgold, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults With Red Blood Cell Transfusion- Dependent Diamond Blackfan Anemia[NCT01464164] | Phase 1/Phase 2 | 19 participants (Actual) | Interventional | 2012-01-31 | Terminated (stopped due to Supporter terminated the study due to no active patients (secondary to travel restrictions due to COVID).) | ||
| Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)[NCT03152058] | Phase 2 | 55 participants (Anticipated) | Interventional | 2017-05-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Complete response is transfusion independence with hemoglobin >9 gm/dl; partial response is transfusion dependence with hemoglobin < 9gm/dl with an increase in reticulocyte count over baseline (NCT01464164)
Timeframe: 9 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Sotatercept Cohort 1 | 0 |
| Sotatercept Cohort 2 | 0 |
| Sotatercept Cohort 3 | 0 |
| Sotatercept With Prednisone Boost Cohort 4a | 0 |
| Sotatercept Cohort 4b | 0 |
| Sotatercept With Prednisone Boost Cohort 5a | 0 |
| Sotatercept Cohort 5b | 0 |
Assess severity of adverse events and relationship to sotatercept according to the currently active minor version of the NCI Common Terminology for Adverse Events version 4.0 (NCT01464164)
Timeframe: 9 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Sotatercept Cohort 1 | 0 |
| Sotatercept Cohort 2 | 0 |
| Sotatercept Cohort 3 | 0 |
| Sotatercept With Prednisone Boost Cohort 4a | 0 |
| Sotatercept Cohort 4b | 0 |
| Sotatercept With Prednisone Boost Cohort 5a | 0 |
| Sotatercept Cohort 5b | 0 |
5 reviews available for prednisone and Fetal Growth Restriction
| Article | Year |
|---|---|
Antiphospholipid syndrome in obstetrics.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Annexin A5; Antibodies, Anticardiolipin; Anticoagu | 2003 |
[Newborn from mother with antiphospholipid syndrome].
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotein I; Female; Fet | 2006 |
Outcomes of pregnancy and the management of immunosuppressive agents to minimize fetal risks in organ transplant patients.
Topics: Azathioprine; Cyclosporine; Female; Fetal Growth Retardation; Fetus; Humans; Immunosuppressive Agent | 1994 |
Effect of drugs on intrauterine growth.
Topics: Abnormalities, Drug-Induced; Animals; Ethanol; Female; Fetal Growth Retardation; Fetus; Growth; Huma | 1979 |
Lupus anticoagulant and pregnancy.
Topics: Aspirin; Autoantibodies; Blood Coagulation Factors; Female; Fetal Death; Fetal Diseases; Fetal Growt | 1985 |
14 other studies available for prednisone and Fetal Growth Restriction
| Article | Year |
|---|---|
Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study.
Topics: Adult; Antirheumatic Agents; Cohort Studies; Female; Fetal Growth Retardation; Gestational Age; Gluc | 2015 |
Diamond-Blackfan anemia, ribosome and erythropoiesis.
Topics: Anemia; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Blood Transfusion; Bone Marrow; Chromosomes, H | 2010 |
[Takayasu's arteritis in pregnancy: report seven cases].
Topics: Adult; Antihypertensive Agents; Cesarean Section; Female; Fetal Growth Retardation; Follow-Up Studie | 2011 |
[Influential factors of systemic lupus erythematosus activity during pregnancy and its relationship with pregnancy outcome].
Topics: Abortion, Spontaneous; Adult; Female; Fetal Death; Fetal Growth Retardation; Gestational Age; Humans | 2006 |
Chronic idiopathic ulcerative colitis. Pregnancy and fetal outcome.
Topics: Adolescent; Adult; Apgar Score; Body Weight; Colitis, Ulcerative; Female; Fetal Growth Retardation; | 1984 |
[Chemotherapy for Hodgkin's disease during pregnancy--a case report].
Topics: Adult; Doxorubicin; Female; Fetal Growth Retardation; Hodgkin Disease; Humans; Prednisone; Pregnancy | 1983 |
Placental insufficiency and its effect on the fetus and adult disease.
Topics: Female; Fetal Growth Retardation; Fetus; Humans; Infant, Newborn; Prednisone; Pregnancy | 1993 |
Lupus anticoagulant. Significance in habitual first-trimester abortion.
Topics: Abortion, Habitual; Adult; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Humans; Lupus Coa | 1993 |
Pregnancy and kidney transplantation: clinical problems and experience.
Topics: Abortion, Spontaneous; Azathioprine; Cesarean Section; Cyclosporine; Female; Fetal Growth Retardatio | 1993 |
Prednisone dosage and pregnancy outcome in renal allograft recipients.
Topics: Abortion, Spontaneous; Adult; Cesarean Section; Female; Fetal Growth Retardation; Humans; Immunosupp | 1997 |
Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin.
Topics: Abortion, Spontaneous; Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Enzym | 1992 |
[Pregnancy after renal transplantation. 27 patients and review of the literature].
Topics: Adult; Azathioprine; Birth Weight; Cesarean Section; Cyclosporine; Drug Therapy, Combination; Female | 1992 |
Polymyositis in pregnancy. A case report and literature review.
Topics: Adult; Female; Fetal Growth Retardation; Humans; Myositis; Physical Examination; Prednisone; Pregnan | 1987 |
Obstetric complications associated with the lupus anticoagulant.
Topics: Abortion, Spontaneous; Aspirin; Blood Coagulation Factors; Blood Coagulation Tests; Female; Fetal De | 1985 |